Wuhan YZY Biopharma Co., Ltd. (HKG:2496)

Hong Kong flag Hong Kong · Delayed Price · Currency is HKD
4.600
-0.200 (-4.17%)
Apr 30, 2026, 6:08 PM HKT
Market Cap891.71M -22.0%
Revenue (ttm)74.40M -38.0%
Net Income-94.29M
EPS-0.49
Shares Out193.85M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume3,200
Average Volume1,440
Open4.500
Previous Close4.800
Day's Range3.900 - 4.600
52-Week Range3.900 - 8.400
Beta0.49
RSI32.27
Earnings DateMar 27, 2026

About Wuhan YZY Biopharma

Wuhan YZY Biopharma Co., Ltd., a biotechnology company, develops bispecific antibody-based therapies for the treatment of cancer, cancer-related complications, and age-related ophthalmologic diseases. The company develops various product candidates for the treatment of malignant ascites, malignant pleural effusion, solid tumors, pancreatic cancer, hepatocellular carcinoma, and other advanced solid tumors; wAMD, DME, and other ocular neovascularization-related diseases; hemophilia; and inflammatory bowel diseases. Wuhan YZY Biopharma Co., Ltd. w... [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2010
Employees 106
Stock Exchange Hong Kong Stock Exchange
Ticker Symbol 2496
Full Company Profile

Financial Performance

In 2025, Wuhan YZY Biopharma's revenue was 66.86 million, a decrease of -37.99% compared to the previous year's 107.81 million. Losses were -84.73 million, -13.18% less than in 2024.

Financial numbers in CNY Financial Statements